Intron-retained GBA transcripts sequester core spliceosomal components (U2AF65, SF3B1, PRPF8) and snRNPs, reducing the available pool for wild-type GBA pre-mRNA processing. This cis-trans interference causes inefficient removal of downstream introns, producing additional aberrant transcripts with PTCs that are degraded by NMD, establishing a positive feedback loop that progressively depletes mature GBA mRNA and protein. The mechanism explains why a minority aberrant isoform disproportionately affects protein output beyond simple haploinsufficiency.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["U2AF2 / SF3B1 / PRPF8 Spliceosome Components"]
B["Dominant-Negative Spliceosome Titration"]
C["Alternative Splicing Dysregulation"]
D["Non-Productive mRNA Splicing"]
E["Protein Dosage Imbalance"]
F["Neurodegeneration ALS / FTD"]
G["Stress Granule Formation"]
A --> B
B --> C
B --> D
C --> E
D --> E
E --> F
F --> G
style A fill:#6a1b9a,stroke:#ce93d8,color:#ce93d8
style F fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style G fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
Median TPM across 13 brain regions for U2AF2, SF3B1, PRPF8; splicing snRNPs from GTEx v10.
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
6 citations6 with PMIDValidation: 0%3 supporting / 3 opposing
✓For(3)
No supporting evidence
No opposing evidence
(3)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
5
1
MECH 5CLIN 1GENE 0EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
Spliceosome component sequestration by aberrant tr…
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-26 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Mechanistic Hypotheses: Intron-Retained GBA Isoform and Protein Reduction
The research question addresses how a specific intron-retaining transcript of GBA (glucosylceramidase, the gene mutated in Gaucher disease) leads to reduced protein levels and enzymatic activity—a phenomenon particularly relevant given that GBA haploinsufficiency is a major Parkinson's disease risk factor.
Hypothesis 1: Ribosome Stalling and Collision-Induced Translational Repression
Title: Cytoplasmic Intron-Retained GBA Transcripts Stall Ribosomes, Activating Collisional Quality Control That Glob
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
Critical Evaluation of GBA Intron-Retention Hypotheses
Hypothesis 1: Ribosome Stalling and Collision-Induced Translational Repression
Weaknesses and Challenges
Nuclear Retention Assumption: The hypothesis assumes intron-retained GBA transcripts "escape nuclear retention," but published evidence indicates the vast majority of intron-retained transcripts are efficiently nuclear-retained, particularly in neuronal cells (Bove et al., 2021; PMID: 33711246). Only a small fraction may escape, making the overall effect potentially negligible.
**Collision Sensor Specificit
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
Practical Feasibility Assessment: GBA Intron-Retention Mechanisms
Surviving Hypotheses
Based on the critique revision, the hypotheses with sufficient mechanistic support to warrant drug development consideration are:
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
{"ranked_hypotheses":[{"title":"Dominant-Negative Spliceosome Titration","description":"Intron-retained GBA transcripts sequester core spliceosomal components (U2AF65, SF3B1, PRPF8) and snRNPs, reducing the available pool for wild-type GBA pre-mRNA processing. This cis-trans interference causes inefficient removal of downstream introns, producing additional aberrant transcripts with PTCs that are degraded by NMD, establishing a positive feedback loop that progressively depletes mature GBA mRNA and protein. The mechanism explains why a minority aberrant isoform disproportionately affects prot
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
If dominant-negative spliceosome titration (U2AF2/SF3B1/PRPF8 dysfunction) drives neurodegeneration through splicing dysregulation, then neurons exposed to spliceosome inhibitors will accumulate mis-spliced transcripts with 3'UTR extensions, increased RISC-loading, and reduced protein output for essential neuronal genes, leading to synaptic dysfunction.
pendingconf: 0.50
Expected outcome: Primary cortical neurons treated with spliceosome inhibitor (pladienolide B, 1-10 nM, 48h) show: >50% of genes with altered splicing (RNA-seq, >30% with extended 3'UTR), increased 3'UTR长度 in synaptic protein transcripts (SYN, PSD95, NR2B), elevated RISC-loading of extended-3'UTR mRNAs, and 40-60% reduction in synaptic protein levels despite unchanged mRNA abundance.
Falsified by: Spliceosome inhibition does not produce 3'UTR extension pattern or synaptic protein loss; neurons maintain normal splicing fidelity and protein synthesis under spliceosome stress, indicating spliceosome dysfunction is not the primary driver of neurodegeneration in this context.
Method: Primary neuron culture: spliceosome inhibition (pladienolide B, spliceostatin A); RNA-seq for splicing patterns; 3'UTR length analysis; RISC-loading assay (AGOs IP); synaptic protein quantification (western blot,绝对定量); electrophysiology for functional validation.
If spliceosome dysfunction is a causal driver of neurodegeneration, then restoring splicing fidelity (e.g., with PRPF8, SF3B1 overexpression, or spliceosome assembly factors) will rescue synaptic function and reduce neurodegeneration markers in patient-derived neurons.
pendingconf: 0.50
Expected outcome: iPSC-derived neurons from neurodegeneration patients with spliceosome component deficiency (U2AF2, SF3B1 mutations) show restored splicing patterns (RNA-seq convergence toward controls) and improved synaptic marker expression (SYN+, PSD95+, electrophysiology) after AAV-mediated wild-type factor overexpression (MOI>100, 14 days), with >60% rescue of neurodegeneration phenotype.
Falsified by: Spliceosome factor restoration does not rescue splicing defects, synaptic protein expression, or neurodegeneration phenotype; disease phenotype persists despite corrected factor levels, indicating spliceosome dysfunction is downstream of primary pathology.
Method: iPSC-derived neuron rescue experiment: patient iPSCs with spliceosome mutations (n≥3 lines), AAV overexpression of wild-type factors, RNA-seq and splicing analysis, synaptic protein quantification, and patch-clamp electrophysiology at 14 and 28 days post-infection.